Gossamer Bio: High-Risk Binary Approaches
Summarize this article with:
Biotech Beast9.01K FollowersFollow5ShareSavePlay(11min)CommentsSummaryGossamer Bio is approaching a binary catalyst with the February 2026 PROSERA phase 3 readout for seralutinib in pulmonary arterial hypertension.PROSERA differs from the phase 2 TORREY study, by focusing on 6MWD as the primary endpoint, enrolling higher-risk patients and more patients outside North America.GOSS is also running a trial of seralutinib in those with pulmonary hypertension associated with interstitial lung disease. That trial only got underway in Q4 '25, however. Pgiam/iStock via Getty Images Gossamer Bio (GOSS) is a biotech developing seralutinib for pulmonary arterial hypertension [PAH]. A readout from a phase 3 trial of seralutinib in PAH is set for February, providing a near-term catalyst, and previous phase 2 data showedThis article was written byBiotech Beast9.01K FollowersFollowScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.